-
Notice of Intent to Publish a Funding Opportunity Announcement for Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)
- Notice NOT-CA-24-048 from the NIH Guide for Grants and Contracts
-
Notice of Special Interest (NOSI): Exploring the Effects of Endocannabinoids and Exogenous Cannabinoids on Brain Development
- Notice NOT-DA-25-030 from the NIH Guide for Grants and Contracts
-
Notice of Cancellation of the June 18, 2024 Application Receipt Date for RFA-EY-23-001 "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)"
- Notice NOT-EY-24-005 from the NIH Guide for Grants and Contracts
-
Notice of Change to NHGRI-specific language in RFA-HG-23-018, Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
- Notice NOT-HG-24-032 from the NIH Guide for Grants and Contracts
-
Notice to change the expiration date of PAR-21-254: Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)
- Notice NOT-HG-24-033 from the NIH Guide for Grants and Contracts
-
Notice to change the expiration date of PAR-21-255: Investigator Initiated Research in Computational genomics and Data Science (R21 Clinical Trial Not Allowed)
- Notice NOT-HG-24-034 from the NIH Guide for Grants and Contracts
-
Notice to Extend PAR-23-093, Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)
- Notice NOT-MH-24-260 from the NIH Guide for Grants and Contracts
-
Notice to Extend PAR-23-101, Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
- Notice NOT-MH-24-261 from the NIH Guide for Grants and Contracts
-
Notice to Extend PAR-23-095, Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)
- Notice NOT-MH-24-265 from the NIH Guide for Grants and Contracts
-
Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research
- Notice NOT-OD-24-096 from the NIH Guide for Grants and Contracts
-
Notice of Fiscal Policies in Effect for FY 2024
- Notice NOT-OD-24-109 from the NIH Guide for Grants and Contracts
-
Notice of Legislative Mandates in Effect for FY 2024
- Notice NOT-OD-24-110 from the NIH Guide for Grants and Contracts
-
Notice of Information: Technical Assistance Webinars for PAR-24-206: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
- Notice NOT-TR-24-024 from the NIH Guide for Grants and Contracts
-
Notice of Special Interest (NOSI) on Catalyzing Research and Training on the Impact of HIV on the Health Across the Lifespan of Women Living with HIV Through Administrative Supplements to Existing Fogarty International Centers HIV Programs
- Notice NOT-TW-24-005 from the NIH Guide for Grants and Contracts
-
Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
- Funding Opportunity RFA-DK-25-005 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
-
Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional)
- Funding Opportunity RFA-MH-25-185 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R01 grant mechanism, while RFA-MH-25-186 uses the R21 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.
-
Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)
- Funding Opportunity RFA-MH-25-186 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R21 grant mechanism, while RFA-MH-25-185 uses the R01 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.
|
|
|